Efficacy and safety of boceprevir plus peginterferon–ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis

This publication has 20 references indexed in Scilit:

• Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir
  Gastroenterology, 2012
• Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
  New England Journal of Medicine, 2011
• Telaprevir for Retreatment of HCV Infection
  New England Journal of Medicine, 2011
• Boceprevir for Untreated Chronic HCV Genotype 1 Infection
  New England Journal of Medicine, 2011
• Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
  New England Journal of Medicine, 2011
• Sustained Virologic Response Prevents the Development of Esophageal Varices in Compensated, Child-Pugh Class A Hepatitis C Virus–Induced Cirrhosis. A 12-Year Prospective Follow-Up Study
  Hepatology, 2010
• Efficacy and Safety of Peginterferon Alfa-2A (40Kd) Plus Ribavirin in Hepatitis C Patients With Advanced Fibrosis and Cirrhosis
  Hepatology, 2010
• Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy
  Gastroenterology, 2009
• Sustained virological response to interferon-α is associated with improved outcome in HCV-related cirrhosis: A retrospective study
  Hepatology, 2007
• Is an “à la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?
  Hepatology, 2000